Metsera, Inc.

MetaVia released new data on 22 April from a Phase I trial of its dual oxyntomodulin analog agonist DA-1726 that it claims might position the drug with a best-in-class safety/tolerability and efficacy

There were six initial public offerings by biopharmaceutical companies on Western stock exchanges during the first quarter of 2025, up from four in the fourth quarter of 2024, but all of the IPOs occu

Included for 2025 are investors, CEOs of small and mid-sized companies, rising employees in larger businesses, and individuals spearheading unique health initiatives worldwide. The 30 individuals list

Big pharma’s appetite for the next big play in the mega-blockbuster obesity market seems insatiable, but two companies aim to feed their pipelines with sizeable collaborations announced on 3 March. Ab